Deutsche Märkte geschlossen

Genetic Technologies Limited (GENE)

NasdaqCM - NasdaqCM Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
1,1500+0,0100 (+0,88%)
Börsenschluss: 04:00PM EST
1,1600 +0,01 (+0,87%)
Nachbörse: 06:39PM EST

Genetic Technologies Limited

60-66 Hanover Street
Fitzroy, VIC 3065
Australia
61 3 8412 7000
https://genetype.com

Sektor(en)Healthcare
BrancheDiagnostics & Research
Vollzeitmitarbeiter52

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Simon MorrissChief Exec. Officer283,96kN/AN/A
Dr. Richard Allman Ph.D.Chief Scientific Officer145,87kN/A1960
Mr. Carl S. Stubbings BScChief Commercial Officer145,53kN/AN/A
Mr. Tony Di Pietro AGIA, B.Com, C.A., CPA, M.A.I.C.D.CFO & Company Sec.N/AN/AN/A
Mr. Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIAConsultantN/AN/AN/A
Mr. Kevin CamilleriChief Exec. Officer of EasyDNAN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Corporate Governance

Genetic Technologies Limiteds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.